Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Fate Therapeutics (NASDAQ: FATE) announced on November 1, 2025 that it granted restricted stock units representing 34,700 shares to three newly hired non-executive employees as inducement awards under its Amended and Restated Inducement Equity Plan.

The grants were approved by the Compensation Committee and were made in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years with 25% vesting on each anniversary of the grant date, subject to continuous employment through each vesting date.

SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on November 1, 2025 the Company granted restricted stock units (RSUs) representing 34,700 shares of its common stock to three newly-hired non-executive employees. The grants were approved by the Compensation Committee of the Company’s Board of Directors and granted under the Company’s Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employees being continuously employed by the Company through each vesting date.

About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Contact:
Christina Tartaglia
Precision AQ
212.362.1200
christina.tartaglia@precisionaq.com

FAQ

How many shares did Fate Therapeutics (FATE) grant as inducement awards on November 1, 2025?

The company granted RSUs representing 34,700 shares to three newly hired non-executive employees.

What is the vesting schedule for the FATE RSU inducement awards granted November 1, 2025?

The RSUs vest over four years with 25% of the shares vesting each anniversary of the grant date, subject to continuous employment.

Under which plan and Nasdaq rule were the FATE inducement awards granted?

The awards were granted under the company's Amended and Restated Inducement Equity Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Who approved the November 1, 2025 RSU grants at Fate Therapeutics (FATE)?

The grants were approved by the Compensation Committee of the company's board of directors.

Do the FATE RSU inducement awards apply to executive employees?

No; the RSUs were granted to three newly-hired non-executive employees.

What condition must be met for each FATE RSU vesting installment?

Each installment vests only if the employee is continuously employed by the company through the applicable vesting date.